Is Senseonics Holdings, Inc. (NASDAQ:SENS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Senseonics Holdings, Inc. at current levels.
The only 365-day implantable CGM has finally shipped, and payer coverage is inflecting just as Dexcom and Abbott hit a wearability ceiling.
Where SENS is headed
Senseonics enters 2027 as the only company selling a continuous glucose monitor that lives under the skin for a full year. That is not a marketing distinction, it is a physical one. Every other CGM on the market falls off, gets snagged, adheses badly, or fails on day 10 or day 14. Eversense 365 sits in the upper arm and reports for 12 months. For a subset of Type 1 and insulin-dependent Type 2 patients, particularly adults who have run out of forearm real estate after years of Dexcom G7 and Libre 3 rotations, that is the difference between compliance and abandonment. Ascensia's commercial engine and the recent expansion of Medicare coverage under the CGM benefit category have finally given the product a real distribution runway.
Read the full Compass Direction on SENS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $7.02).
See the full SENS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Senseonics Holdings, Inc. (NASDAQ:SENS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Senseonics Holdings, Inc. at current levels. The only 365-day implantable CGM has finally shipped, and payer coverage is inflecting just as Dexcom and Abbott hit a wearability ceiling.
What is SENS's Compass Score?
Senseonics Holdings, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for SENS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SENS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.